Telix Manufacturing Solutions
Telix Manufacturing Solutions (TMS) is our global network of facilities designed to deliver radiopharmaceutical doses to patients worldwide. Given the short half-life of these products, highly efficient manufacturing and logistics are essential to ensure timely delivery. As adoption of radiopharmaceuticals continues to grow, scalable production and reliable supply chains are critical to meeting increasing demand.
TMS capabilities
Clinical and commercial GMP (good manufacturing process) dose production
Isotope processing and supply chain security
Radiochemistry & bioconjugation expertise
Precursor preparation and test labelling
Support for drug discovery and clinical translation
Last-mile delivery of finished unit doses to clinical sites
Explore the TMS network
TMS global facilities
-
RLS Radiopharmacies
One of the United States’ leading radiopharmacy networks, accredited by The Joint Commission, with 29 state-of-the-art facilities across the United States. Each site is built to leading industry standards and staffed by experienced Nuclear Pharmacists, Radiation Safety Officers, and a dedicated courier fleet, all dedicated to delivering patient doses from bench to bedside.
-
TMS Seneffe
This state-of-the-art GMP production facility, located in Belgium’s RadioPharma Valley, is one of the largest of its kind in Europe. Serving as Telix’s primary manufacturing site for the region, the facility also functions as a central hub for collaborative research and development. It features a dedicated laboratory for alpha therapies, reinforcing its role in advancing innovative radiopharmaceutical solutions for both clinical and commercial applications.
-
TMS North Melbourne
Purpose-built for early-stage R&D and radiopharmaceutical production, the facility is situated in Melbourne’s Parkville Precinct, close to major hospitals, globally recognized academic institutions, and prominent research centres. This strategic location supports our mission to accelerate clinical development and foster collaboration within one of Australia’s most prominent biomedical hubs.
-
TMS Yokohama
Our first cyclotron facility in the Asia Pacific region serves as a hub for commercial and clinical drug product supply, as well as research and development initiatives. This facility represents a significant step in expanding our footprint in Asia, ensuring regional access to advanced radiopharmaceuticals.
-
ARTMS
Located in Vancouver, British Columbia (Canada), ARTMS specializes in decentralized, large-scale cyclotron production of medical isotopes to strengthen the radioisotope supply chain for our commercial products. The core technology platform, the QUANTM Irradiation System™ (QIS™) facilitates more efficient, high-yield production of commercially important isotopes, helping to meet the growing demand for therapeutic and imaging radiopharmaceuticals to ensure uninterrupted access for patients worldwide.
-
IsoTherapeutics
Located just outside Houston, Texas (U.S.), our in-house specialty facility supports capabilities in radiochemistry, bioconjugation and isotope processing. ITG’s team are leaders in radiolabeling and antibody conjugates for use in developing novel therapeutic and imaging agents.
-
Telix Targeting Technologies (T3)
Located in Los Angeles, California (U.S.), T3 is a state-of-the-art R&D facility with expertise in discovery, protein engineering and radiopharmaceutical development. T3 offers end-to-end preclinical capabilities, from antibody screening to in-vivo studies, and features a novel biologics platform designed to advance the next generation of Telix precision medicines.
One of the United States’ leading radiopharmacy networks, accredited by The Joint Commission, with 29 state-of-the-art facilities across the United States. Each site is built to leading industry standards and staffed by experienced Nuclear Pharmacists, Radiation Safety Officers, and a dedicated courier fleet, all dedicated to delivering patient doses from bench to bedside.
This state-of-the-art GMP production facility, located in Belgium’s RadioPharma Valley, is one of the largest of its kind in Europe. Serving as Telix’s primary manufacturing site for the region, the facility also functions as a central hub for collaborative research and development. It features a dedicated laboratory for alpha therapies, reinforcing its role in advancing innovative radiopharmaceutical solutions for both clinical and commercial applications.
Purpose-built for early-stage R&D and radiopharmaceutical production, the facility is situated in Melbourne’s Parkville Precinct, close to major hospitals, globally recognized academic institutions, and prominent research centres. This strategic location supports our mission to accelerate clinical development and foster collaboration within one of Australia’s most prominent biomedical hubs.
Our first cyclotron facility in the Asia Pacific region serves as a hub for commercial and clinical drug product supply, as well as research and development initiatives. This facility represents a significant step in expanding our footprint in Asia, ensuring regional access to advanced radiopharmaceuticals.
Located in Vancouver, British Columbia (Canada), ARTMS specializes in decentralized, large-scale cyclotron production of medical isotopes to strengthen the radioisotope supply chain for our commercial products. The core technology platform, the QUANTM Irradiation System™ (QIS™) facilitates more efficient, high-yield production of commercially important isotopes, helping to meet the growing demand for therapeutic and imaging radiopharmaceuticals to ensure uninterrupted access for patients worldwide.
Located just outside Houston, Texas (U.S.), our in-house specialty facility supports capabilities in radiochemistry, bioconjugation and isotope processing. ITG’s team are leaders in radiolabeling and antibody conjugates for use in developing novel therapeutic and imaging agents.
Located in Los Angeles, California (U.S.), T3 is a state-of-the-art R&D facility with expertise in discovery, protein engineering and radiopharmaceutical development. T3 offers end-to-end preclinical capabilities, from antibody screening to in-vivo studies, and features a novel biologics platform designed to advance the next generation of Telix precision medicines.